FutureChem Co.,Ltd Company Description

FutureChem Co.,Ltd engages in the research and development, production, and sale of radiopharmaceuticals in South Korea.

The company offers PDVUE, a positron emission tomography (PET) radiopharmaceutical diagnostic medicine for Parkinson’s disease; Alzavue, a radiopharmaceutical for Aalzheimer's disease; and [18F]FDG, a PET radiopharmaceutical for the treatment of cancer.

Its products in pipeline include 18F-FC303 and 177Lu-FC705 for the treatment of prostate cancer; 18F-FMT for the treatment of brain tumor; 18F-FC505, for the treatment of atherosclerotic plaque; and 18F-FC211, for the treatment of Alzheimer’s disease.

FutureChem Co.,Ltd was founded in 1999 and is headquartered in Seoul, South Korea.

FutureChem Co.,Ltd

Country	South Korea
Founded	1999
Industry	In Vitro and In Vivo Diagnostic Substances
Employees	66
CEO	Dae-Yoon Chi

Contact Details

Address: PyeongHwa Building Seoul, 04794 South Korea
Phone	82 2 497 3114
Website	futurechem.co.kr

Stock Details

Ticker Symbol	220100
Exchange	KOSDAQ
Fiscal Year	January - December
Reporting Currency	KRW
SIC Code	2835

Key Executives

Name	Position
Dae-Yoon Chi	Chief Executive Officer